The Skinny-Label Case: A Unanimous Supreme Court Sides with the Generic
Just this morning, the Supreme Court issued its slip opinion on Hikma v. Amarin, the most recent “skinny-label” case, and it did so unanimously. Justice Jackson, writing for all nine, reversed the Federal Circuit and held that Amarin’s lawsuit against the generic manufacturer Hikma cannot survive a motion to dismiss. I had planned to spread this story across a short series (with the first one going live today — the life of an academic!), yet the Court’s timing collapsed it into one post. So let me take it from the top: how the generic-drug bargain works, how a fish-oil pill turned into a Supreme Court case, what the Justices made of it, and why this quiet dispute is one of the more consequential drug-pricing rulings in years.

